Prevention and treatment of osteoporosis;Prevención y tratamiento de la osteoporosis

Endocrinologia y Nutricion

Volumn 50, Issue 1, 2003, Pages 1-7

  Munoz Torres M ^a,b   Alonso, G ^a   Mezquita Raya, P ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

ADOLESCENCE; AGED; BLEEDING; BONE DENSITY; BONE MINERALIZATION; BREAST CANCER; BREAST DISEASE; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COLLES FRACTURE; DETERIORATION; EDITORIAL; ESTROGEN THERAPY; EXERCISE; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MALE; MENOPAUSE; META ANALYSIS; NUTRITION; NUTRITIONAL REQUIREMENT; OSTEOPOROSIS; OVARY CANCER; QUALITY OF LIFE; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS; VAGINA DISEASE; VITAMIN D DEFICIENCY;

EID: 0037285227     PISSN: 15750922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1575-0922(03)74488-X     Document Type: Editorial

References (66)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. JAMA 2001;285:785-95.
2. Ray NF, Chan JK, Thamer, M. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from The National Osteoporosis Fundation. J Bone Mineral Res 1997;12:24-35.
3. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Fundation, 1998.
4. Sociedad Española de Investigaciones Óseas y Metabolismo Mineral (SEIOMM). Osteoporosis postmenopáusica. Guía de Práctica Clínica. 2001. Disponible en: http://www.seiomm.org
5. Faulkner KB. Bone matters: Are density increases necessary to reduce fracture risk? J Bone Miner Res 2000;15:183-7.
6. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-6.
7. Melton LJ III, Alkinson EJ, Cooper C. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999;10:214-21.
8. Black DM, Arden NK, Palermo L, for the Study of Osteoporosis Fractures Research Group. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Mineral Res 1999;14:821-8.
9. Lindsay R, Silverman SL, Cooper C, Cauley JA. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285:320-3.
10. Endsrud KE, Thompson DE (Fracture Intervention Trial Research Group) Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. J Am Geriatr Soc 2000;48:241-9.
11. Bauer DC. Osteoporotic fractures: ignorance is bliss? Am J Med 2000;109:338-9.
12. Freedman KB, Kaplan FS, Bilker WB. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg Am. 2000;82A:1063-70.
13. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: WHO Technical Report Series no. 843.
14. AACE 2001 Medical Guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Prac 2001;7:294-312.
15. Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loos? A double-blind controlled clinical study. N Engl J Med 1987;316:173.
16. Grainge MJ, Coupland CA, Cliffe SJ, Chilvers CE, Hosting DJ (Nottinghan EPIC Study Group). Cigarette smoking, alcohol and caffeine comsumption, and bone mineral density in post-menopausal women. Osteoporos Int 1998;8:355-63.
17. Chapuy MC, Arlot ME, Duboeuf F. Vitamin D3 calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327:1637.
18. Mezquita Raya P, Muñoz-Torres M. Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women. J Bone Miner Res 2001;16:1408-15.
19. Prince RL, Smith M, Dick M. Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991;325:1189.
20. Slemenda CW, Longcope C, Zhou L. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997;100:1755.
21. Behre HM, Kliesch S, Leifke E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82:2386.
22. Muñoz-Torres M, Mezquita Raya P. The contribution of IGF-I to skeletal integrity in postmenopausal women. Clin Endocrinol 2001;55:759-66.
23. Ortego M, Muñoz-Torres M. Bone mineral density, sex steroids, and mineral metabolism in premenopausal smokers. Calcif Tissue Int 1994;55:403-7.
24. Delmas PD, Bjarnason NH, Mitlak BH. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in post menopausal women. N Engl J Med 1997;337:1641-7.
25. Herd RJ, Balena R, Blake GM, Ryan PJ, Fogelman I. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Am J Med 1997;103:92-9.
26. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998;83:396-402.
27. Hosking D, Chilvers CED, Christiansen C, Raun P, Wasnick R, Ross P, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Eng J Med. 1998;338:485-92.
28. AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis. J Flo Med Assoc 1996;83:552-65.
29. Maxim P, Ettinger B, Spitalny GM. Fracture protection provided by long-term estrogen treatment. Osteoporos Int 1995;5:23-9.
30. Santoro N, Miller NT. Menopause and the menopausal state. Curr Pract Med 1998;1:423-8.
31. Muñoz-Torres M, Mezquita P. Nuevos planteamientos en el papel de los estrógenos sobre el metabolismo óseo. Med Clín (Barc) 1999;113:292-3.
32. Rosen CJ, Kessenich CR. The pathophysiology and treatment of postmenopausal osteoporosis: an evidence-based approach to estrogen replacement therapy. Endocrinol Metab Clin North Am 1997;26:295-311.
33. Manson, JE, Martin KA. Postmenopausal hormone-replacement therapy. N Engl J Med 2001;345:34-40.
34. Torgenson D, Bell Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891-7.
35. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
36. Genant HK, Lucas J, Weiss S. For the Estratab/Osteoporosis Study Group. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium and lipid levels. Arch Intern Med 1997;157:2609-15.
37. Recker RR, Davis KM, Dowd RM. The effect of low-dose continuos estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial. Ann Intern Med 1999;130:897-904.
38. Avioli LV. The role of calcitonin in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998;27:411-8.
39. Overgaard K, Hansen MA, Jensen SB. Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556-61.
40. Muñoz Torres M, Mezquita P. La calcitonina. Drugs Today 1999;35(Suppl 1):1-12.
41. Chesnut CH III, Silverman S, Andriano K, for The PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000;109:267-76.
42. Cummings SR, Chapurlat RD. What PROOF proves about calcitonin and clinical trails. Am J Med 2000;109:330-1.
43. Liberman UA, Weiss SR, Bröll J. For The Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
44. Favus M, Emkey R, Leite M. Five-year treatment of osteoporosis in postmenopausal women with oral alendronate: effects on bone mass and turnover and safety. J Bone Miner Res 1997;12(Suppl 1)S150.
45. Tonino RP, Meunier PJ, Emkey R, for the Alendronate Phase III Osteoporosis Treatment Study Group. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000;85:3109-15.
46. Black DM, Cummings SR, Karf DB. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
47. Cummings SR, Black DM, Thompson DE. Effect of alendronate on risk fracture in women with low bone density but without vertebral fractures. JAMA 1998;280:2077-82.
48. Pols HAP, Felsenberg D, Hanley DA, Stepan J, Muñoz-Torres M. A multinational randomized trial of the effects of Alendronate on bone mineral density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT Study. Osteoporos International 1999;9:461-8.
49. Karpf DB, Shapiro DR, Seeman E. Prevention of non-vertebral fractures by alendronate: a meta-analysis. JAMA 1997;277: 1159-64.
50. Schnitzer T, Bone HG, Crepaldi G, for the Alendronate Once-Weekly Study Group. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000;12:1-12.
51. Reginster J-Y, Minne HW, Sorensen OH. For The Vertebral Efficacy With Risendronate Therapy (VERT) Study Group. Osteoporosis Int 2000;11:83-91.
52. Harris ST, Watts NB, Genant HK, for the Vertebral Efficacy With Risendronate Therapy (VERT) Study Group. Effects of risendronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a ramdomized, controlled trial. JAMA 1999;282:1344-52.
53. McClung MR, Gensens P, Miller PD, for the Hip Intervention Program Study Group. Effect of risendronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
54. Muñoz-Torres M, Mezquita P, López-Rodríguez F. Moduladores selectivos de los receptores estrogénicos. En: Díaz Curiel M, editor. Actualización de Osteoporosis. Madrid: Fondo Editorial FHOEMO, 2001; p. 135-43.
55. Spencer CP, Morris EP, Rymer JM. Selective estrogen receptor modulators: women's panacea for the next millennium? Am J Obstet Gynecol 1999;180:763-70.
56. Balfour JA, Goa KL. Raloxifene. Drugs Aging 1998;12:335-41.
57. Ettinger B, Black DM, Mirtlak BH, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
58. Cummings SR, Eckert S, Krueger KA. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-97.
59. Cauley JA, Norton L, Lippman ME. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001;65:125-34.
60. Barret-Connor E, Grady D, Sashegyi A. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA 2002;287:847-57.
61. Cosman F, Lindsay R. Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence. Calcif Tissue Int 1998;62:475-80.
62. Morley P, Whitfield JF, Willick GE. Parathyroid hormone: an anabolic treatment for osteoporosis. Curr Pharm Des 2001;7: 671-87.
63. Neer RM, Arnaud CD, Zanchetta JR. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344: 1434-41.
64. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiophatic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000;85:3069-76.
65. Lane NE, Sánchez S, Modin GW, Genant HK, Pierini E, Arnaud CD. Parathyroid-hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 1998;102:1627-33.
66. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001; 16:1846-53.